French pharmaceutical company Servier announced an acquisition deal with Kaerus Bioscience for their Fragile X syndrome drug candidate KER-0193. The oral small molecule, a BK channel modulator, showed safety and biomarker-driven proof of mechanism in Phase 1 trials, supporting advancement to planned Phase 2 studies in the US and Europe. Fragile X syndrome is a leading inherited cause of autism and intellectual disability with no approved therapies. Servier’s acquisition highlights its commitment to expanding a neurology pipeline focused on rare diseases with high unmet needs.